Nektar Therapeutics (NASDAQ:NKTR) SVP Maninder Hora sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, April 5th. The stock was sold at an average price of $101.75, for a total transaction of $2,035,000.00. Following the transaction, the senior vice president now owns 127,394 shares of the company’s stock, valued at $12,962,339.50. The transaction was disclosed in a filing with the SEC, which is available through this link.
NASDAQ NKTR traded up $10.58 on Monday, hitting $104.45. The company’s stock had a trading volume of 2,857,513 shares, compared to its average volume of 3,136,327. Nektar Therapeutics has a 1-year low of $17.33 and a 1-year high of $111.36. The company has a debt-to-equity ratio of 2.79, a quick ratio of 5.63 and a current ratio of 5.82. The stock has a market cap of $15,105.83, a P/E ratio of -189.91 and a beta of 1.73.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.14. Nektar Therapeutics had a negative net margin of 31.42% and a negative return on equity of 156.85%. The company had revenue of $95.47 million during the quarter, compared to analysts’ expectations of $36.96 million. During the same period in the prior year, the company posted ($0.28) earnings per share. Nektar Therapeutics’s revenue for the quarter was up 154.9% compared to the same quarter last year. analysts predict that Nektar Therapeutics will post -1.33 earnings per share for the current fiscal year.
Several brokerages have issued reports on NKTR. Canaccord Genuity upped their price target on shares of Nektar Therapeutics to $94.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. HC Wainwright set a $125.00 price target on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Monday. Jefferies Group upped their price target on shares of Nektar Therapeutics to $103.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Mizuho restated a “buy” rating and issued a $89.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, February 14th. Finally, Zacks Investment Research cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $63.75.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.